Seqll

SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. Its services include RNA sequencing and DNA sequencing. The company was founded by William C. St. Laurent and Daniel R. Jones in 2013 and is headquartered in Billercia, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BILLERICA, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Lyneer Investments, LLC (“Lyneer”), the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp. (“Atlantic”), and related parties, pursuant to which Lyneer will become a wholly-owned subsidiary of SeqLL.

SeqLL Inc. Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition Corp.

SeqLL (NASDAQ: SQL ) stock is on the rise Monday with heavy trading despite a lack of news from the molecule sequencing technology company. Getting into that trading, some 1.7 million shares of SQL stock have changed hands as of this writing.

Why Is SeqLL (SQL) Stock Up 43% Today?

BILLERICA, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the first quarter ended March 31, 2023.

SeqLL Provides First Quarter 2023 Financial Results

BILLERICA, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services, today announced its operating and financial results for the fourth quarter and year ended December 31, 2022.

SeqLL Announces Fourth Quarter and Year End 2022 Financial Results

BILLERICA, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (Nasdaq: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, today announced the closing of its previously announced registered direct offering of 2,000,000 shares of common stock at a purchase price of $0.90 per share of common stock (the “Offering”).

SeqLL Inc. Announces Closing of $1.8 Million Registered Direct Offering

BILLERICA, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a securities purchase agreement (the “Agreement”) with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering (the “Offering”). The gross proceeds to the Company from the Offering are estimated to be approximately $1.8 million before deducting the placement agent's fees and other Offering expenses.

SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering

Shares of SeqLL Inc. SQL, -38.69% more than doubled on heavy volume ahead of Friday's open, in the wake of the genetic sequencing company's announcement earlier in the week about an product development agreement with the Federal Bureau of Investigation. The stock skyrocketed 128.6% on volume of 16.1 million shares premarket, enough to make it the biggest gainer and most active stock listed on major U.S. exchanges.

SeqLL stock rockets on heavy volume again, in wake of 2-year development pact with FBI

SeqLL (NASDAQ: SQL ) stock is taking off on Friday morning despite a lack of news from the forensic company. Instead, it looks like traders can thank heavy trading for the boost to SQL's stock price this morning.

Why Is SeqLL (SQL) Stock Up 126% Today?

SeqLL (NASDAQ: SQL ) stock is seeing massive gains on Tuesday after signing a new contract with a government agency. Specifically, the company has signed a two-year Cooperative Research and Development Agreement (CRADA) with the Federal Bureau of Investigation (FBI).

Why Is SeqLL (SQL) Stock Up 256% Today?

Intelligent Bio Solutions Inc

Kiora Pharmaceuticals

Lizhi

Innovative Eyewear Inc

Sidus Space

Vaccinex Inc

Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?

7 Penny Stocks To Watch With Big News In February; Time To Buy?

BILLERICA, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL”, NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced the establishment of a two-year Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Justice's Federal Bureau of Investigation (FBI). Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL's True Single Molecule Sequencing (tSMS®) platform.

SeqLL Announces CRADA with the FBI

BILLERICA, Mass., Dec. 13, 2022 (GLOBE NEWSWIRE) --  SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced that Brian Paras has joined the company as Chief Business Officer.

Brian Paras joins SeqLL as Chief Business Officer

BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the third quarter ended September 30, 2022.

SeqLL Provides Third Quarter 2022 Financial Results

BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL's single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

BILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL's single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022.

SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference

BILLERICA, Mass., June 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, announced that on June 21, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for common shares were below $1.00 per share for the last 30 consecutive business days.

SeqLL Inc. Receives Nasdaq Notification Regarding Minimum Bid Requirements

BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced a new study utilizing its single-molecule epigenetic profiling technology was published in the peer-reviewed journal Cell Reports.

SeqLL's Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal

BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the first quarter ended March 31, 2021, and provided a corporate update.

SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

Forge Global Holdings Inc

Gyrodyne

Integrated Media Technology Ltd

Oxbridge Re Holdings Limited

Tuscan Holdings Corp II - Units (1 Ord shares & 1/2 Wrt)

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It's a measure put in place to help restore and bring order to the markets.

6 Stocks Halted In Thursday's Session

BILLERICA, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

SeqLL Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.

SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of distinguished and world-renowned leaders of the scientific community. The SAB will discuss with management potential new development opportunities that leverage the Company's unique True Single Molecule Sequencing (tSMS®) technology across the “omics” fields, as well as advise management with their existing collaborative, scientific, & development partnerships. Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.

SeqLL Announces Formation of Scientific Advisory Board

WOBURN, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the closing of the sale of an additional 189,000 shares of common stock at the initial public offering price of $4.24 per share, pursuant to the partial exercise of the underwriters' over-allotment option, in connection with its initial public offering that closed on August 31, 2021, resulting in gross proceeds of approximately $801,360. After giving effect to the exercise of the over-allotment option, the total gross proceeds of the initial public offering increased to approximately $13,810,950.

SeqLL Inc. Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering

Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc.

News for Seqll Stock (SQL)